Polarean Imaging PLC Comment re: share purchase (6114Z)
January 15 2024 - 2:00AM
UK Regulatory
TIDMPOLX
RNS Number : 6114Z
Polarean Imaging PLC
15 January 2024
Polarean Imaging Plc
("Polarean" or the "Company")
Comment re: share purchase
Polarean Imaging plc (AIM: POLX), a commercial-stage medical
device leader in advanced magnetic resonance imaging ("MRI") of the
lungs, notes the TR-1 announcements released on 12 January 2024
showing the sale of 9.5 million Polarean shares held by Amati
Global Investors Ltd to NUKEM Isotopes GmbH ("NUKEM Isotopes"), a
strategic partner and investor in the Company. This transaction
highlights the significant support NUKEM Isotopes has in Polarean,
and has increased NUKEM Isotopes's Polarean holding to 10.458%.
NUKEM Isotopes GmbH is a leading trading company for stable
isotopes used in different fields for various applications. They
have established reliable partnerships with gas manufacturers for
the production of highly pure noble gases. The company is located
in Alzenau, Germany.
Enquiries :
Polarean Imaging plc www.polarean.com / www.polarean-ir.com
Christopher von Jako, Ph.D, Chief Via Walbrook PR
Executive Officer
Charles Osborne, Chief Financial
Officer
Stifel Nicolaus Europe Limited (NOMAD and
Sole Corporate Broker) +44 (0)20 7710 7600
Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare
Investment Banking)
Nick Adams / Nick Harland (Corporate Broking)
Walbrook PR Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com
Anna Dunphy / Phillip Marriage Mob: +44 (0)7876 741 001 / +44 (0)7867
984 082
About Polarean (www.polarean.com)
The Company and its wholly-owned U.S. subsidiary, Polarean, Inc.
are revenue-generating, medical imaging technology companies. The
Company aspires to revolutionise pulmonary medicine by bringing the
power and safety of MRI to the respiratory healthcare community
which is desperately in need of new modern solutions to evaluate
lung function. Polarean is dedicated to researching, developing,
and commercialising these novel imaging solutions with their
non-invasive and radiation-free functional MRI platform. The
Company strives to address the global unmet medical needs of more
than 500 million patients worldwide suffering from chronic
respiratory disease. Polarean is a leader in the field of
hyperpolarisation science and has successfully developed the first
and only hyperpolarised Xenon MRI contrast agent (XENOVIEW(TM)) to
be FDA-approved in the United States. The Company also
commercialises the systems, software, and accessories to support
fully integrated modern respiratory imaging operations. Founded in
2012, with offices in Durham, NC, and London, United Kingdom,
Polarean is committed to increasing global awareness of and broad
access to its XENOVIEW MRI technology platform. For the latest news
and information about Polarean, please visit www.polarean.com .
PLC-RNS-2326
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCZZGMMMDKGDZM
(END) Dow Jones Newswires
January 15, 2024 02:00 ET (07:00 GMT)
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Polarean Imaging (LSE:POLX)
Historical Stock Chart
From Oct 2023 to Oct 2024